Most cited papers from Universidad de Navarra

Universidad de Navarra

What are the most cited papers from Universidad de Navarra?

The most cited paper from Universidad de Navarra is "MDS clinical diagnostic criteria for Parkinson's disease" (Ronald B. Postuma, Daniela Berg, Matthew Stern et al., 2015), with 7,758 citations. Next come "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial" (6,590) and "Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)" (6,023).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 1,340 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	MDS clinical diagnostic criteria for Parkinson's disease Ronald B. Postuma, Daniela Berg, Matthew Stern et al. · Movement Disorders	Oct 2015	7,758
2	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Roy S. Herbst, Paul Baas, Dong‐Wan Kim et al. · The Lancet	19 Dec 2015	6,590
3	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) Daniel J. Klionsky et al. · Autophagy Open access2,467 authors	2 Jan 2016	6,023
4	Gene regulation by long non-coding RNAs and its biological functions Luisa Statello, Chunjie Guo, Ling‐Ling Chen et al. · Nature Reviews Molecular Cell Biology ReviewOpen access	22 Dec 2020	5,304
5	International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma S. Vincent Rajkumar et al. · The Lancet Oncology Open access	26 Oct 2014	5,031
6	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease European Alzheimer's Disease Initiative (EADI) et al. · Nature Genetics ReviewOpen access184 authors	27 Oct 2013	4,711
7	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial Anthony B. El-Khoueiry et al. · The Lancet Open access	20 Apr 2017	4,384
8	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update María Reig, Alejandro Forner, Jordi Rimola et al. · Journal of Hepatology Open access	19 Nov 2021	4,345
9	The Business Model: Recent Developments and Future Research Christoph Zott, Raphael H Amit, Lorenzo Massa · Journal of Management	2 May 2011	4,313
10	Social entrepreneurship research: A source of explanation, prediction, and delight Johanna Mair, Ignasi Lanuza Martí · Journal of World Business	4 Oct 2005	3,992
11	Corporate Social Responsibility Theories: Mapping the Territory Elisabet Garriga, Domènec Melé · Journal of Business Ethics	Aug 2004	3,991
12	Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial Jonathan E. Rosenberg et al. · The Lancet Open access	5 Mar 2016	3,762
13	Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts Ramón Estruch et al. · New England Journal of Medicine Open access	13 Jun 2018	3,630
14	International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma Shaji Kunnathu Kumar et al. · The Lancet Oncology	26 Jul 2016	3,102
15	Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Axel Hauschild et al. · The Lancet	25 Jun 2012	3,009
16	The emerging role of lncRNAs in cancer Maite Huarte · Nature Medicine	Nov 2015	2,920
17	The synchronization of chaotic systems Stefano Boccaletti, Jürgen Kurths, Grigory V. Osipov et al. · Physics Reports	Aug 2002	2,782
18	Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition) 1 Daniel J. Klionsky et al. · Autophagy Open access2,930 authors	2 Jan 2021	2,743
19	Socioemotional Wealth in Family Firms Pascual Berrone, Cristina Cruz, Luis R. Gómez‐Mejía · Family Business Review	15 Feb 2012	2,717
20	Hepatocellular carcinoma Josep Maria Llovet, Jessica Zucman‐Rossi, Eli Pikarsky et al. · Nature Reviews Disease Primers Review	14 Apr 2016	2,705
21	Dendritic cells in cancer immunology and immunotherapy Stefanie K. Wculek, Francisco J. Cueto, Adriana M. Mujal et al. · Nature reviews. Immunology Review	29 Aug 2019	2,642
22	Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab Nadeem Riaz et al. · Cell Open access	13 Oct 2017	2,629
23	Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer Daniel Öhlund et al. · The Journal of Experimental Medicine Open access	23 Feb 2017	2,621
24	Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma Nikhil C. Munshi et al. · New England Journal of Medicine Open access	24 Feb 2021	2,554
25	In Search of Complementarity in Innovation Strategy: Internal R&D and External Knowledge Acquisition Bruno Cassiman, Reinhilde Veugelers · Management Science	2006	2,521
26	On strategic networks José-Carlos Jarillo · Strategic Management Journal	1988	2,481
27	Long non-coding RNAs: definitions, functions, challenges and recommendations John S. Mattick et al. · Nature Reviews Molecular Cell Biology ReviewOpen access	3 Jan 2023	2,438
28	From Strategy to Business Models and onto Tactics Ramon Casadesus‐Masanell, Joan E. Ricart · Long Range Planning	30 Mar 2010	2,367
29	Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer Antonio González-Martı́n et al. · New England Journal of Medicine Open access	28 Sep 2019	2,318
30	Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Fátima Cardoso, Stella Kyriakides, Shinji Ohno et al. · Annals of Oncology Open access	22 May 2019	2,287
31	Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2 Vanessa Monteil, Hyesoo Kwon, Patricia Prado et al. · Cell Open access	24 Apr 2020	2,271
32	Inactivation of the DNA-Repair Gene MGMT and the Clinical Response of Gliomas to Alkylating Agents Manel Esteller, Jesús García‐Foncillas, Esther Andion et al. · New England Journal of Medicine Open access	9 Nov 2000	2,251
33	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial Arjun Vasant Balar et al. · The Lancet Open access	7 Dec 2016	2,230
34	ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma Nicole Concin et al. · International Journal of Gynecological Cancer Open access	23 Dec 2020	2,012
35	Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data Monique Maas, Patty J. Nelemans, Vincenzo Valentini et al. · The Lancet Oncology	8 Aug 2010	1,983
36	Necessity as the mother of ‘green’ inventions: Institutional pressures and environmental innovations Pascual Berrone, Andréa Fosfuri, Liliana Gelabert et al. · Strategic Management Journal	21 Dec 2012	1,950
37	Economic Effects of Coronavirus Outbreak (COVID-19) on the World Economy Nuno Fernandes · SSRN Electronic Journal PreprintOpen access	2020	1,932
38	Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer Mario Fernández Fraga et al. · Nature Genetics	13 Mar 2005	1,931
39	Socioemotional Wealth and Corporate Responses to Institutional Pressures: Do Family-Controlled Firms Pollute Less? Pascual Berrone, Cristina Cruz, Luis R. Gómez‐Mejía et al. · Administrative Science Quarterly	Mar 2010	1,843
40	The Paleozoic Origin of Enzymatic Lignin Decomposition Reconstructed from 31 Fungal Genomes Dimitrios Floudas et al. · Science Open access	28 Jun 2012	1,840
41	Hydrogen Production From Water Electrolysis: Current Status and Future Trends Alfredo Ursúa, Luis M. Gandía, Pablo Sanchis · Proceedings of the IEEE Open access	21 Jun 2011	1,693
42	The Bind that Ties: Socioemotional Wealth Preservation in Family Firms Luis R. Gómez‐Mejía, Cristina Cruz, Pascual Berrone et al. · Academy of Management Annals	Jun 2011	1,689
43	Effects of a Mediterranean-Style Diet on Cardiovascular Risk Factors Ramón Estruch, Miguel Ángel Martínez-González, Dolores Corella et al. · Annals of Internal Medicine	4 Jul 2006	1,685
44	A Short Screener Is Valid for Assessing Mediterranean Diet Adherence among Older Spanish Men and Women Helmut Schröder, Montserrat Fitó, Ramón Estruch et al. · Journal of Nutrition Open access	20 Apr 2011	1,645
45	Equivalent-circuit models for split-ring resonators and complementary split-ring resonators coupled to planar transmission lines Juan Domingo Baena, Jordi Bonache, Ferran Martı́n et al. · IEEE Transactions on Microwave Theory and Techniques	Apr 2005	1,623
46	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee Elı́as Campo et al. · Blood Open access	2 Jun 2022	1,603
47	Global epidemiology of hyperthyroidism and hypothyroidism Peter Nicholas Taylor, Diana Albrecht, Anna Scholz et al. · Nature Reviews Endocrinology Review	23 Mar 2018	1,579
48	Entrepreneurship in and around institutional voids: A case study from Bangladesh Johanna Mair, Ignasi Lanuza Martí · Journal of Business Venturing	4 Jun 2008	1,548
49	Force Triggers YAP Nuclear Entry by Regulating Transport across Nuclear Pores Alberto Elósegui-Artola, Ion Andreu, Amy E. M. Beedle et al. · Cell Open access	26 Oct 2017	1,537
50	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma Ghassan K. Abou‐Alfa et al. · NEJM Evidence Open access	6 Jun 2022	1,534

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.